Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Contemp Clin Trials. 2018 Nov 6;76:55–63. doi: 10.1016/j.cct.2018.11.006

Table 1.

Baseline characteristics for participants enrolled inPhase I (n = 528), those not randomized (n = 83), and those randomized to Phase II (n = 445).

Phase I participants
M (SD) or n (%)
Participants not
randomized to Phase II
M (SD) or n (%)
Participants randomized
to Phase II
M (SD) or n (%)

Age (years) 54.5 (10.7) 49.9 (11.8) 55.4 (10.3)

Body mass index (BMI, kg/m2) 36.6 (3.8) 37.3 (4.3) 36.4 (3.7)

Obesity Class

 Class I (BMI = 30.0 to 34.9) 200 (37.9%) 28 (33.7%) 172 (38.6%)

 Class II (BMI = 35.0 to 39.9) 223 (42.2%) 30 (36.1%) 193 (43.4%)

 Class III (BMI = 40.0 to 45.0) 105 (19.9%) 25 (30.1%) 80 (18.0%)

Gender (female) 434 (82%) 66 (79.5%) 368 (83%)

Education, highest level completed

 < High school 12 (2%) 1 (1.2%) 11 (2%)

 High school or GED 280 (53%) 53 (63.9%) 227 (51%)

 Associate’s degree 66 (13%) 12 (14.5%) 54 (12%)

 Bachelor’s degree 117 (22%) 14 (16.9%) 103 (23%)

 Advanced degree 53 (10%) 3 (3.6%) 50 (11%)

Race/ethnicity
 White, Non-Hispanic/Latino 391 (74%) 63 (75.9%) 328 (74%)
 Black, Non-Hispanic/Latino 100 (19%) 18 (21.7%) 82 (18%)
 Other, Non-Hispanic/Latino 16 (3%) 0 (0.0%) 16 (4%)
 White, Hispanic/Latino 16 (3%) 2 (2.4%) 14 (3%)
 Black, Hispanic/Latino 1 (0%) 0 (0.0%) 1 (0%)
 Other, Hispanic/Latino 4 (1%) 0 (0.0%) 4 (1%)

Annual household income

 < $20,000 67 (13%) 18 (21.7%) 49 (11%)

 $20,000-$34,999 93 (18%) 11 (13.3%) 82 (18%)

 $35,000-$49,999 93 (18%) 14 (16.9%) 79 (18%)

 $50,000-$74,000 123 (23%) 16 (19.3%) 107 (24%)

 > $75,000 120 (23%) 20 (24.1%) 100 (22%)

 Unknown/refused 32 (6%) 4 (4.8%) 28 (6%)